| Literature DB >> 33802226 |
María Plaza-Oliver1,2, Emilio L Cano3,4, María Mar Arroyo-Jimenez1,2, Matías Gámez3, María Victoria Lozano-López1,2, Manuel J Santander-Ortega1,2.
Abstract
The success on the design of new oral nanocarriers greatly depends on the identification of the best physicochemical properties that would allow their diffusion across the mucus layer that protects the intestinal epithelium. In this context, particle tracking (PT) has arisen in the pharmaceutical field as an excellent tool to evaluate the diffusion of individual particles across the intestinal mucus. In PT, the trajectories of individual particles are characterized by the mean square displacement (MSD), which is used to calculate the coefficient of diffusion (D) and the anomalous diffusion parameter (α) as MSD=4Dτα. Unfortunately, there is no stablished criteria to evaluate the goodness-of-fit of the experimental data to the mathematical model. This work shows that the commonly used R2 parameter may lead to an overestimation of the diffusion capacity of oral nanocarriers. We propose a screening approach based on a combination of R2 with further statistical parameters. We have analyzed the effect of this approach to study the intestinal mucodiffusion of lipid oral nanocarriers, compared to the conventional screening approach. Last, we have developed software able to perform the whole PT analysis in a time-saving, user-friendly, and rational fashion.Entities:
Keywords: R software; data processing; diffusion; oral lipid nanocarriers; particle tracking; screening of trajectories
Year: 2021 PMID: 33802226 PMCID: PMC8001040 DOI: 10.3390/pharmaceutics13030370
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Three possible scenarios in the regression analysis of experimental Mean Square Displacement (MSD) vs. lag time (τ) data (dots) to the theoretical model (dashed line). (a) Erratic trajectories due to uncontrollable experimental artifacts (). (b) Nanoparticles unable to diffuse across the intestinal mucus (; ). (c) Nanoparticles able to diffuse across the intestinal mucus ().
Figure 2MSD estimation as a function of lag time. The statistical error of the estimation (vertical bars) increases as lag time rises.
Figure 3Impact of on (a) Dm/Dw, (b) α value of PSNPs.
Figure 4Distribution of trajectories (%) of mucoadhesive (black columns) and mucodiffusive (grey columns) PSNPs as a function of . Normally, high values are associated with diffusive trajectories.
Main results of particle tracking experiments performed for digested lipid nanocarriers obtained after following different approaches for the screening of trajectories showing poor goodness-of-fit.
| Screening Approach |
| NPs | NPs (%) | |
|---|---|---|---|---|
| 0.37 | 0.064 | 6965 | 100.0 | |
| 0.47 | 0.083 | 5259 | 75.5 | |
| 0.52 | 0.094 | 4532 | 65.1 | |
| 0.57 | 0.108 | 3883 | 55.8 | |
| 0.62 | 0.126 | 3236 | 46.5 | |
| 0.66 | 0.148 | 2646 | 38.0 | |
| 0.71 | 0.181 | 2090 | 30.0 | |
| 0.76 | 0.225 | 1591 | 22.8 | |
| 0.83 | 0.299 | 1102 | 15.8 | |
| 0.92 | 0.443 | 627 | 9.0 | |
| 0.32 | 0.064 | 6681 | 95.9 |
Main results of particle tracking experiments performed for non-digested lipid nanocarriers obtained after following different approaches for the screening of trajectories showing poor goodness-of-fit.
| Screening Approach |
| NPs | NPs (%) | |
|---|---|---|---|---|
| 0.22 | 0.009 | 1167 | 100.0 | |
| 0.35 | 0.014 | 741 | 63.5 | |
| 0.41 | 0.017 | 605 | 51.8 | |
| 0.46 | 0.020 | 517 | 44.3 | |
| 0.50 | 0.023 | 449 | 38.5 | |
| 0.53 | 0.025 | 396 | 33.9 | |
| 0.56 | 0.029 | 342 | 29.3 | |
| 0.59 | 0.035 | 282 | 24.2 | |
| 0.66 | 0.044 | 211 | 18.1 | |
| 0.78 | 0.072 | 122 | 10.5 | |
| 0.22 | 0.009 | 1113 | 95.4 |
Figure 5Optimized decision-tree for particle tracking (PT) screening of trajectories showing poor goodness-of-fit. (a) Conventional approach, based on and (b) proposed approach, based on a combination of and residuals sum of squares (RSS) error measurements.
Figure 6Distribution of D/D results of non-digested lipid nanocarrier after following different goodness-of-fit screenings.
Figure 7Reduction on the mean time required by non-digested (black columns) and digested (grey columns) lipid nanocarriers to diffuse across an intestinal porcine mucus layer of 100 µm based on a single (R2) or combination (R2 + RSS) screening approach (dotted line) (* p < 0.05).
Figure 8Particle populations considered to calculate the diffusion capacity of (a) diffusive PSNPS control and (b) adhesive PSNPS control after following different approaches to evaluate the goodness-of-fit.